EPRX: Rounding Bottom detected on 9 Oct 2026

EPRX is forming a rounding bottom pattern with a structure score of 12.0, indicating a gentle, arc-like recovery from recent lows. The stock is trading at $7.57, positioned 44.19% above its 52-week low of approximately $4.21 and 18.78% below its 52-week high. Key support sits at $5.63, with resistance at $9.01. The breakout score of 13.0 and volume score of 9.0 suggest moderate pattern quality—current volume is 637,045 shares (70% of 20-day average), slightly below normal. The overall score of 64 reflects a setup with decent structural integrity but lacking exceptional volume confirmation. The rounding bottom suggests a shift from downtrend to consolidation, with RSI at 46.47 indicating neutral momentum neither overbought nor oversold.

EPRX has a critical catalyst approaching: Phase 2b interim readout for the randomized RESOLVE trial (EP-104GI) expected in Q4 2026. Recent developments supporting the stock include updated long-duration data from the highest-dose cohort of the RESOLVE study in eosinophilic esophagitis and completion of transfer to a higher Nasdaq market tier. In the highest-dose cohort, two of three patients maintained remission at 52 weeks, with no treatment-related serious adverse events reported across all 10 cohorts. Wedbush initiated coverage with an Outperform rating in late September and reiterated a Buy view on 1 October, while Stifel and HC Wainwright maintain Buy ratings. The company expects existing cash and warrant proceeds to fund operations into H2 2028, providing a runway for clinical development without near-term financing pressure.

A successful breakout above the $9.01 resistance would target a conservative measured move of $7.98, though the pattern structure suggests potential extension higher. Historical rounding bottom patterns show win probability of 67.21%, indicating better-than-random success odds. For confirmation, volume should expand above the 20-day average of 910,640 shares—current relative volume of 0.7x is acceptable but volume absorption near resistance would strengthen conviction. Invalidation occurs below $5.63 support, where the pattern breaks down and indicates the rounding bottom failed to establish a sustainable reversal. The pattern suggests the stock is stabilizing after recent weakness (down 6.31% over one month) and positioning for acceleration into Q4 catalysts.

Sector sentiment is supportive, but company-specific execution remains more important than momentum alone. The biotechnology sector itself faces headwinds, as EPRX operates in Health Care with sector regime score of -0.09 (bearish), which conflicts with the bullish market regime (0.86). Clinical trial execution risk is substantial—interim Phase 2b readout could disappoint or delay, eroding the current pattern strength. MACD histogram is negative (-0.1182), indicating momentum weakness despite price structure. Beta of 0.84 provides some downside protection but limits upside participation. Volume ratio of 0.7 and relative volume of 0.7 both suggest below-average liquidity, increasing slippage risk on larger positions. With cash runway into H2 2028, dilution risk from future financing remains, particularly if clinical trials face setbacks. ATR volatility at 8.06% is moderate for biotech, but RSI at neutral territory provides no edge; watch for deterioration below 40 that would signal accelerating selling.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.